Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 8;13(11):e0206853.
doi: 10.1371/journal.pone.0206853. eCollection 2018.

Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: A meta-analysis of case-control studies

Yao Xiong  1 , Qian Zhang  2 , Jiaxiang Ye  1 , Shan Pan  1 , Lianying Ge  1
Affiliations

Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: A meta-analysis of case-control studies

Yao Xiong et al. PLoS One. .

Abstract

Conflicting results have been obtained regarding the association between X-ray repair cross complementation group 1 (XRCC1) and susceptibility to hepatocellular carcinoma (HCC). In this study, associations between HCC and three polymorphisms (Arg194Trp, Arg280His, and Arg399Gln) were evaluated using a meta-analysis approach. PubMed, Web of Science, Cochrane Library, the Chinese National Knowledge Infrastructure, and the Wanfang standard database were systematically searched to identify all relevant case-control studies published through March 2018. A total of 32 case-control studies, including 13 that evaluated Arg194Trp, 14 that evaluated Arg280His, and 26 that evaluated Arg399Gln, were analyzed. In the entire study population, XRCC1 Arg399Gln was significantly associated not only with overall risk of HCC (homozygous model, OR = 1.61, 95% CI: 1.40-1.85, P < 0.05; recessive model, OR = 1.40, 95% CI: 1.23-1.59, P < 0.05) but also with the risk of HCC in Chinese patients (homozygous model, OR = 1.78, 95% CI: 1.53-2.08, P < 0.05; recessive model, OR = 1.47, 95% CI: 1.27-1.70, P < 0.05). Limiting the analysis to studies demonstrating Hardy-Weinberg equilibrium (HWE), the results were consistent and robust. Similarly, a significant association between XRCC1 Arg399Gln and HCC risk was found in healthy controls in the general population but not in hospital controls. Trial sequential analysis (TSA), false-positive report probabilities (FPRP), and combined genotype analysis revealed that XRCC1 Arg399Gln is mainly associated with susceptibility to liver cancer. However, there was no association between Arg194Trp or Arg280His and the risk of HCC. These results, indicating that the Arg399Gln polymorphism of XRCC1 is associated with the risk of HCC in the Chinese population, provide a basis for the development of improved detection and treatment approaches.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram of study selection for the meta-analysis.
CNKI, Chinese National Knowledge Infrastructure Database. WFSD, the Wanfang standard database.
Fig 2
Fig 2. Forest plot of the association between XRCC1 Arg399Gln polymorphism and HCC risk under a homozygous model.
Fig 3
Fig 3. Forest plot of the association between XRCC1 Arg399Gln polymorphism and HCC risk under a recessive model.
Fig 4
Fig 4. Forest plot of the association between XRCC1 Arg399Gln polymorphism and HCC risk under a dominant model.
Fig 5
Fig 5. Funnel plot to detect publication bias in data on XRCC1 Arg399Gln polymorphism according to a homozygous model.
Fig 6
Fig 6. Funnel plot to detect publication bias in data on XRCC1 Arg399Gln polymorphism according to a recessive model.
Fig 7
Fig 7. Funnel plot to detect publication bias in data on XRCC1 Arg399Gln polymorphism according to a dominant model.
Fig 8
Fig 8. Trial sequential analysis for XRCC1 Arg194Trp gene polymorphism under the allele contrast model.
Fig 9
Fig 9. Trial sequential analysis for XRCC1 Arg280His gene polymorphism under the allele contrast model.
Fig 10
Fig 10. Trial sequential analysis for XRCC1 Arg399Gln gene polymorphism under the allele contrast model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30. Epub 2018/01/04. 10.3322/caac.21442 . - DOI - PubMed
    1. Zuo TT, Zheng RS, Zhang SW, Zeng HM, Chen WQ. Incidence and mortality of liver cancer in China in 2011. Chin J Cancer. 2015; 34:508–513. Epub 2015/10/15;34(11):508–13. 10.1186/s40880-015-0056-0 . - DOI - PMC - PubMed
    1. Seguí N, Mina LB, Lázaro C, Sanz-Pamplona R, Pons T, Navarro M, Bellido F, López-Doriga A, Valdés-Mas R, Pineda M, et al.: Germline mutations in FAN1 cause hereditary colorectal cancer by impairing DNA repair. Gastroenterology. 2015; 149(3): 563–566. Epub 2015/06/05; - PubMed
    1. Tasnim T, Al-Mamun MMA, Nahid NA, Islam MR, Apu MNH, Bushra MU, et al. Genetic variants of SULT1A1 and XRCC1 genes and risk of lung cancer in Bangladeshi population. Tumour Biol. 2017; 39(11):1010428317729270 10.1177/1010428317729270 . - DOI - PubMed
    1. Huang X, Liu C, Cui Y, Zhang H, Liu Y, Zhou X, et al. Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett. 2017; 13(2):704–714. Epub 2016 Dec 14. 10.3892/ol.2016.5496 17(1):758. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances